Home
Overview
Results of the early benefit assessment
G-BA procedures
Resolutions
Subpopulations
Indication areas (G-BA)
Eye diseases
Skin diseases
Cardiovascular diseases
Infectious diseases
Respiratory system diseases
Hematopoietic diseases
Musculoskeletal system diseaeses
Nervous system diseases
Genitourinary system diseases
Digestive system diseases
Oncological diseases
Mental illnesses
Metabolic diseases
Other diseases
Orphan drugs
Results of reassessments
G-BA request (§13 VerfO)
Manufacturer's request (§14 VerfO)
Orphan drugs, exceeding turnover limit
Orphan drugs, loss of status
G-BA requirements
Procedures
G-BA resolutions
G-BA active procedures
G-BA procedures not completed
Fundamentals
AMNOG step by step
Detailed analysis for each G-BA resolution
Interactive analysis
Interactive analysis: Excel export
Interactive analysis: Bookmarks
Interactive analysis: dimensions
Intelligent search
Monthly report
AMNOG app
Calculation methods
EMA regulatory procedure
Changes in legal regulations
Technical terms English-German
Contact
Contact form
Legal notice
Privacy policy
Search G-BA resolutions
Login
Login
Username
Password
Oops, an error occurred! Request: 0c79b3d01991c
